Since the development of the first‐generation Tyrosine Kinase Inhibitor (TKI), it has played a crucial role in the treatment of BCR::ABL1‐positive acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.